Hua Medicine (Shanghai) Ltd. (HUA MEDICINE-B) aksje

Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA and small molecule GLP-1 for T2D and obesity; combination with insulin to treat insulin sparing in T2D; second generation glucokinase (GK) inhibitor and GK NAM for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and Dorzagliatin for the treatment of T2D-Drug Naïve, T2D-Metformin Tolerated, RWE study for Diabetes Remission, MODY-2, Diabetes prevention IGT2NGT, Frailty, Early AD, and CFRD. Hua Medicine (Shanghai) Ltd. was incorporated in 2011 and is headquartered in Shanghai, China.